Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 86.6% in August

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 5,487 shares, a decrease of 86.6% from the July 30th total of 41,083 shares. Based on an average daily volume of 46,742 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in APRE. DRW Securities LLC acquired a new position in Aprea Therapeutics during the fourth quarter worth approximately $103,000. Jane Street Group LLC purchased a new stake in Aprea Therapeutics in the fourth quarter valued at approximately $40,000. Finally, AIGH Capital Management LLC boosted its holdings in shares of Aprea Therapeutics by 174.1% in the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after acquiring an additional 645,000 shares during the period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wedbush reduced their price objective on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Finally, Oppenheimer started coverage on Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.07.

Aprea Therapeutics Price Performance

Shares of APRE opened at $0.95 on Wednesday. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.69. The stock has a market cap of $11.96 million, a PE ratio of -0.88 and a beta of 1.52. The firm has a fifty day moving average price of $0.70 and a 200 day moving average price of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative return on equity of 47.60% and a negative net margin of 4,405.59%. As a group, equities analysts expect that Aprea Therapeutics will post -0.32 EPS for the current fiscal year.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.